Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -309.44% is 144% below its 5-year average of -126.57%, around the middle of its 5-year range (-839.56%–28.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.14% above its 12-month average of -574.50%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -309.44%.
RETURN ON EQUITY (ROE)
-309.44%
RETURN ON EQUITY (ROE) AVG TTM
-574.50%
RETURN ON EQUITY (ROE) AVG 3Y
-424.74%
RETURN ON EQUITY (ROE) AVG 5Y
-126.57%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+46.14%
CURRENT VS 3Y AVG
+27.15%
CURRENT VS 5Y AVG
-144.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-636.59%
vs the sector median at left
Humacyte, Inc.
Market Cap
$80.30M
Return on Equity (ROE)
-309.44%
TTM Avg
-574.50%
3Y Avg
-424.74%
5Y Avg
-126.57%
Market Cap
$79.61M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$81.20M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
Market Cap
$81.22M
Return on Equity (ROE)
-28.85%
TTM Avg
-24.95%
3Y Avg
-20.92%
5Y Avg
-19.20%
Market Cap
$79.03M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$78.59M
Return on Equity (ROE)
-6.05%
TTM Avg
-96.60%
3Y Avg
16.82%
5Y Avg
35.21%
Market Cap
$82.29M
Return on Equity (ROE)
232.78%
TTM Avg
-18.33%
3Y Avg
-28.65%
5Y Avg
-29.96%
Market Cap
$78.29M
Return on Equity (ROE)
-55.97%
TTM Avg
-55.58%
3Y Avg
-51.87%
5Y Avg
-151.31%
Market Cap
$82.47M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $80.30M | -309.44% | -574.50% | -424.74% | -126.57% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | -85.65% | -57.41% | -45.73% | -8.61% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -130.67% | -143.13% | -106.90% | -90.63% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -28.85% | -24.95% | -20.92% | -19.20% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | -114.06% | -50.52% | -45.18% | -45.18% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -6.05% | -96.60% | 16.82% | 35.21% |
| LENSAR Inc (LNSR)vs › | $82.29M | 232.78% | -18.33% | -28.65% | -29.96% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -55.97% | -55.58% | -51.87% | -151.31% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -150.95% | -77.89% | -62.90% | -47.80% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | -116.74% | -1373.57% | -759.05% | -574.01% |
ROE
-309.4%
ROA
-70.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -309.44% |
| 2026-03-31 | -839.56% |
| 2025-03-31 | -215.48% |
| 2024-03-31 | -404.19% |
| 2023-12-31 | -817.78% |
| 2023-09-30 | -241.64% |
| 2023-06-30 | -145.09% |
| 2023-03-31 | -35.54% |
| 2022-12-31 | -10.23% |
| 2022-09-30 | 28.94% |
| 2022-06-30 | 19.72% |
| 2022-03-31 | -25.03% |
| 2021-12-31 | -21.67% |
| 2021-09-30 | -112.41% |
| 2021-06-30 | -173.36% |
| 2021-03-31 | -124.68% |
| 2020-12-31 | -94.13% |
